# BRCAAway (NCT03012321)

> Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

No report yet. It can be ordered.

- Drugs tested: olaparib plus abiraterone; olaparib
- Indication: metastatic castration-resistant prostate cancer with DNA repair defects

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03012321
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Northwestern University
- Conditions: Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
- Interventions: Olaparib; Abiraterone Acetate; Prednisone
- Enrollment: 70
- Primary outcome: Objective Progression Free Survival (PFS)

## Questions raised in the commentary

_Automated from the 40 newest of 164 indexed sources (Jan 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether upfront combination is preferable to sequencing
- How applicable the findings are after prior ARPI exposure
- Whether combination treatment causes greater toxicity

Also discussed: treatment breaks.

## Indexed commentary on BRCAAway so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 98
- YouTube: 33
- Podcasts: 31
- Bluesky threads: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=brcaaway-nct03012321

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03012321", "email": "<work email>"}; the inbox owner confirms by the emailed link.